RxDoctor Payments Data

Robert Hyzy, MD

Pulmonary Disease · Ann Arbor, MINPI 1437231347

Payments from drug & device makers

$27,399in general payments, 2019–2025

Across 24 payments — averaging $1141.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • Omeros Corporation$4K
  • Rigel Pharmaceuticals, Inc.$2K
  • Boehringer Ingelheim$2K
  • Amgen$161
  • plus $15 from 1 others

What the payments were for

  • Consulting fees$13,97580%
  • Speaking & faculty fees$1,80010%
  • Travel & lodging$1,1757%
  • Food & beverage$4513%
  • Education$150%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,399 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$54,622
Medicare patients
300
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate86$1,129,695
EsbrietPirfenidone24$246,080
Pirfenidone49$80,145
Spiriva RespimatTiotropium Bromide34$27,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,803
Breo ElliptaFluticasone/Vilanterol25$12,354
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate46$10,460
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$9,920
Incruse ElliptaUmeclidinium Bromide19$9,022
SymbicortBudesonide/Formoterol Fumarate24$8,864
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$7,410
Atovaquone18$6,089
Mycophenolate Mofetil21$5,443
Wixela InhubFluticasone Propion/Salmeterol21$5,249
Serevent DiskusSalmeterol Xinafoate12$4,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$1,600$1,157,583120 claims
AstraZenecaSymbicort$15$8,86424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →